📊 PLRX Key Takeaways
Is Pliant Therapeutics, Inc.. (PLRX) a Good Investment?
Pliant Therapeutics is a pre-commercial stage pharmaceutical company with zero revenue and approximately 4-5 months of cash runway at current $128.3M annual burn rates, creating critical near-term capital requirement risk. While year-over-year loss improvements (29% better net income, 30% better EPS) and zero debt demonstrate operational progress, the fundamental mismatch between $45.4M cash reserves and accelerating burn rate necessitates an urgent capital raise with significant dilution risk to existing shareholders.
Why Buy Pliant Therapeutics, Inc.. Stock? PLRX Key Strengths
- Net loss and EPS improving year-over-year indicating operational efficiency gains or reduced spend
- Zero long-term debt and strong relative balance sheet with $181.2M stockholders equity and no leverage
- Exceptional short-term liquidity with 12.0x current and quick ratios providing flexibility for near-term obligations
PLRX Stock Risks: Pliant Therapeutics, Inc.. Investment Risks
- Zero revenue indicating pre-commercial stage with binary outcome risk dependent entirely on clinical/regulatory success
- Critical cash runway of only 4-5 months at current burn rate requiring dilutive capital raise within quarters
- Substantial operating cash burn of $128.3M annually against limited assets, indicating unsustainable burn trajectory without revenue inflection
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash position relative to operating runway
- Clinical trial advancement, regulatory milestone achievements, and potential commercialization timelines
- Capital raise announcements, financing terms, and shareholder dilution from equity issuance
Pliant Therapeutics, Inc.. (PLRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.00x current ratio provides a solid financial cushion.
PLRX Profit Margin, ROE & Profitability Analysis
PLRX vs Healthcare Sector: How Pliant Therapeutics, Inc.. Compares
How Pliant Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pliant Therapeutics, Inc.. Stock Overvalued? PLRX Valuation Analysis 2026
Based on fundamental analysis, Pliant Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pliant Therapeutics, Inc.. Balance Sheet: PLRX Debt, Cash & Liquidity
PLRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pliant Therapeutics, Inc..'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-3.47 indicates the company is currently unprofitable.
PLRX Revenue Growth, EPS Growth & YoY Performance
PLRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$37.5M | $-0.70 |
| Q2 2024 | N/A | -$37.5M | $-0.70 |
| Q1 2024 | N/A | -$37.5M | $-0.67 |
| Q3 2023 | N/A | -$28.1M | $-0.65 |
| Q2 2023 | $248.0K | -$28.1M | $-0.70 |
| Q1 2023 | $1.2M | -$28.1M | $-0.67 |
| Q3 2022 | $1.5M | -$22.8M | $-0.65 |
| Q2 2022 | $1.8M | -$22.8M | $-0.64 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pliant Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PLRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pliant Therapeutics, Inc.. (CIK: 0001746473)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLRX
What is the AI rating for PLRX?
Pliant Therapeutics, Inc.. (PLRX) has an AI rating of STRONG SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLRX's key strengths?
Claude: Net loss and EPS improving year-over-year indicating operational efficiency gains or reduced spend. Zero long-term debt and strong relative balance sheet with $181.2M stockholders equity and no leverage.
What are the risks of investing in PLRX?
Claude: Zero revenue indicating pre-commercial stage with binary outcome risk dependent entirely on clinical/regulatory success. Critical cash runway of only 4-5 months at current burn rate requiring dilutive capital raise within quarters.
What is PLRX's revenue and growth?
Pliant Therapeutics, Inc.. reported revenue of $0.0.
Does PLRX pay dividends?
Pliant Therapeutics, Inc.. does not currently pay dividends.
Where can I find PLRX SEC filings?
Official SEC filings for Pliant Therapeutics, Inc.. (CIK: 0001746473) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLRX's EPS?
Pliant Therapeutics, Inc.. has a diluted EPS of $-2.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PLRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pliant Therapeutics, Inc.. has a STRONG SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PLRX stock overvalued or undervalued?
Valuation metrics for PLRX: ROE of -82.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PLRX stock in 2026?
Our dual AI analysis gives Pliant Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLRX's free cash flow?
Pliant Therapeutics, Inc..'s operating cash flow is $-128.3M, with capital expenditures of $374.0K.
How does PLRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -82.4% (avg: 15%), current ratio 12.00 (avg: 2).